Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.

CYP2D6 poor metabolizer (genetic or phenoconversion by inhibitors) → aripiprazole accumulation → metabolic abnormalities

This retrospective cohort study evaluates the impact of CYP2D6 phenotype on metabolic abnormalities in patients prescribed aripiprazole. Patients co-prescribed CYP2D6 inhibitors are classified as phenoconverted poor metabolizers. Results quantify the differential impact of CYP2D6 phenotype on measurable metabolic parameters, highlighting the clinical relevance of phenoconversion in aripiprazole monitoring.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Aripiprazole is one of the most prescribed antipsychotics, and CYP2D6 is a major substrate. This study illustrates the concept of phenoconversion — often overlooked in practice despite functionally converting a normal into a poor metabolizer — and its measurable metabolic consequences. Another argument for systematic CYP2D6 genotyping in psychiatry.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10